WO1995018615A1 - Procede de traitement de l'inflammation neurogene - Google Patents

Procede de traitement de l'inflammation neurogene Download PDF

Info

Publication number
WO1995018615A1
WO1995018615A1 PCT/DK1995/000003 DK9500003W WO9518615A1 WO 1995018615 A1 WO1995018615 A1 WO 1995018615A1 DK 9500003 W DK9500003 W DK 9500003W WO 9518615 A1 WO9518615 A1 WO 9518615A1
Authority
WO
WIPO (PCT)
Prior art keywords
ethyl
ethoxy
dihydro
mixture
added
Prior art date
Application number
PCT/DK1995/000003
Other languages
English (en)
Inventor
Knud Erik Andersen
Uffe Bang Olsen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to JP7518276A priority Critical patent/JPH09507849A/ja
Priority to AU13111/95A priority patent/AU1311195A/en
Priority to BR9506453A priority patent/BR9506453A/pt
Priority to EP95904410A priority patent/EP0735872A1/fr
Publication of WO1995018615A1 publication Critical patent/WO1995018615A1/fr
Priority to NO962812A priority patent/NO962812L/no
Priority to FI962750A priority patent/FI962750A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne un procédé de traitement de l'inflammation neurogène chez un sujet et consiste à administrer audit sujet, une dose utile d'un composé de la formule (I).
PCT/DK1995/000003 1994-01-04 1995-01-03 Procede de traitement de l'inflammation neurogene WO1995018615A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP7518276A JPH09507849A (ja) 1994-01-04 1995-01-03 神経性情報の処理方法
AU13111/95A AU1311195A (en) 1994-01-04 1995-01-03 A method of treating neurogenic inflammation
BR9506453A BR9506453A (pt) 1994-01-04 1995-01-03 Processo de tratamento de inflamação neurogênica em um individuo necessitando do mesmo
EP95904410A EP0735872A1 (fr) 1994-01-04 1995-01-03 Procede de traitement de l'inflammation neurogene
NO962812A NO962812L (no) 1994-01-04 1996-07-03 Fremgangsmåte for behandling av neurogen inflammasjon
FI962750A FI962750A (fi) 1994-01-04 1996-07-04 Menetelmä neurogeenisen tulehduksen hoitamiseksi

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK2094 1994-01-04
DK0020/94 1994-01-04

Publications (1)

Publication Number Publication Date
WO1995018615A1 true WO1995018615A1 (fr) 1995-07-13

Family

ID=8088844

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1995/000003 WO1995018615A1 (fr) 1994-01-04 1995-01-03 Procede de traitement de l'inflammation neurogene

Country Status (13)

Country Link
EP (1) EP0735872A1 (fr)
JP (1) JPH09507849A (fr)
CN (1) CN1142183A (fr)
AU (1) AU1311195A (fr)
BR (1) BR9506453A (fr)
CA (1) CA2180239A1 (fr)
CZ (1) CZ198396A3 (fr)
FI (1) FI962750A (fr)
HU (1) HUT76281A (fr)
IL (1) IL112223A0 (fr)
NO (1) NO962812L (fr)
WO (1) WO1995018615A1 (fr)
ZA (1) ZA9530B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997022342A1 (fr) * 1995-12-15 1997-06-26 Novo Nordisk A/S Nouveau procede
US7417040B2 (en) 2004-03-01 2008-08-26 Bristol-Myers Squibb Company Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2965639A (en) * 1960-12-20 New basically substituted azepine
EP0221572A2 (fr) * 1985-11-08 1987-05-13 Warner-Lambert Company Acides 3-pipéridine ou 3-pyridine carboxyliques et leurs dérivés
WO1992020658A1 (fr) * 1991-05-17 1992-11-26 Novo Nordisk A/S Nouveaux acides carboxyliques heterocycliques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2965639A (en) * 1960-12-20 New basically substituted azepine
EP0221572A2 (fr) * 1985-11-08 1987-05-13 Warner-Lambert Company Acides 3-pipéridine ou 3-pyridine carboxyliques et leurs dérivés
WO1992020658A1 (fr) * 1991-05-17 1992-11-26 Novo Nordisk A/S Nouveaux acides carboxyliques heterocycliques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DRUG DESIGN AND DELIVERY, Volume 4, 1989, E. FALCH, P. KROGSGAARD-LARSEN, "Gaba Uptake Inhibitors Containing Mono- and Diarylmethoxyalkyl N-Substituents", page 205 - page 215. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997022342A1 (fr) * 1995-12-15 1997-06-26 Novo Nordisk A/S Nouveau procede
US7417040B2 (en) 2004-03-01 2008-08-26 Bristol-Myers Squibb Company Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3

Also Published As

Publication number Publication date
FI962750A0 (fi) 1996-07-04
IL112223A0 (en) 1995-03-30
HU9601826D0 (en) 1996-09-30
CZ198396A3 (en) 1997-01-15
CN1142183A (zh) 1997-02-05
BR9506453A (pt) 1997-09-02
NO962812L (no) 1996-09-04
ZA9530B (en) 1996-07-04
EP0735872A1 (fr) 1996-10-09
FI962750A (fi) 1996-09-04
HUT76281A (en) 1997-07-28
CA2180239A1 (fr) 1995-07-13
JPH09507849A (ja) 1997-08-12
AU1311195A (en) 1995-08-01
NO962812D0 (no) 1996-07-03

Similar Documents

Publication Publication Date Title
US5688788A (en) N-substituted azaheterocyclic carboxylic acids and esters thereof
US5741791A (en) Method of reducing blood glucose
EP0820451B1 (fr) Nouveaux composes heterocycliques
EP0585314B1 (fr) Nouveaux acides carboxyliques heterocycliques
US5747481A (en) Heterocyclic compounds
EP0735872A1 (fr) Procede de traitement de l'inflammation neurogene
EP0869954B1 (fr) Composes heterocycliques utiles dans le traitement d'une inflammation neurogenique
EP0820443B1 (fr) Composes heterocycliques pour le traitement du diabete
US5827856A (en) Method of treating insulin resistance
US6613791B1 (en) N-substituted azaheterocyclic carboxylic acids and their use
WO1996031473A1 (fr) Nouveaux composes heterocycliques
WO1996031502A1 (fr) Nouveaux composes heterocycliques

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95191801.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KE KG KP KR KZ LK LR LT LV MD MG MN MW MX NO NZ PL RO RU SD SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1995904410

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2180239

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PV1996-1983

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 962750

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1995904410

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1996-1983

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV1996-1983

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1995904410

Country of ref document: EP